Global Research Output of Lutetium-177 PSMA in Prostate Cancer: Bibliometric and Altmetric Analyses

Rakan Al-Rashdan; Haneen Al-Abdallat; Mike Machaba Sathekge; Siroos Mirzaei; Mohammed Shahait; Khaled Al-Khawaldeh; Ahmed Saad Abdlkadir; Szeting Lee; Akram Al-Ibraheem

doi:10.1055/a-2221-3036

Global Research Output of Lutetium-177 PSMA in Prostate Cancer: Bibliometric and Altmetric Analyses

Nuklearmedizin. 2024 Jan 23. doi: 10.1055/a-2221-3036. Online ahead of print.

Authors

Affiliations

¹ Nuclear Medicine, King Hussein Cancer Center (KHCC), Al-Jubeiha, Jordan.
² School of Medicine, The University of Jordan, Al-Jubeiha, Jordan.
³ Nuclear Medicine, University of Pretoria, Pretoria, South Africa.
⁴ Institute of Nuclear Medicine with PET-Center, Wilhelminen Hospital, Vienna, Austria.
⁵ Surgery Department, Clemenceau Medical Center Dubai, Dubai, United Arab Emirates.
⁶ Nuclear Medicine, King Hussein Medical Center (KHMC), Amman, Jordan.
⁷ Department of Molecular Imaging and Therapy, Austin Health, Victoria, Australia.

PMID: 38262473
DOI: 10.1055/a-2221-3036

Abstract

Aim: The integration of innovative radio-pharmaceutical agents targeting prostate-specific membrane antigen (PSMA) within nuclear medicine has transformed prostate cancer detection and management. This study aims to investigate the present landscape of [¹⁷⁷Lu]Lu-PSMA in prostate cancer, elucidating trends, global contributions, scholarly outlets, institutions, and thematic concentrations with an aim to inform forthcoming research endeavors.

Methods: We systematically probed the Scopus repository for relevant [¹⁷⁷Lu]Lu-PSMA literature. An assessment of bibliometric and altmetric data was carried out. Finally, we assessed the correlation between the altmetric attention scores and the number of citations for the retrieved data.

Results: Spanning January 2015 to July 2023, the study encompassed 466 articles concerning [¹⁷⁷Lu]Lu-PSMA therapy for prostate cancer. Predominant citation accolades gravitated towards metastatic castration-resistant prostate cancer investigations and assessments of [¹⁷⁷Lu]Lu-PSMA therapy's safety and efficacy. Further research encompassed adverse effects linked to [¹⁷⁷Lu]Lu-PSMA intervention, including xerostomia, thrombocytopenia, anemia, and fatigue. Germany emerged as the primary academic contributor, with The Journal of Nuclear Medicine dominating publications (n = 55). A moderate significant correlation was detected between the number of citations and altmetric attention scores .

Conclusion: The findings highlight the growing interest and advancements in the utilization of [¹⁷⁷Lu]Lu-PSMA therapy in prostate cancer and offer a comprehensive global perspective on future research directions.